Abstract:Objective To compare the effect of Amiodarone and Lidocaine in the treatment of severe ventricular arrhythmias.Methods Sixty-two patients with severe ventricular arrhythmias admitted to cardiology department of our hospital from February 2017 to February 2019 were selected as the research subjects,and all patients were divided into the control group(n=31)and the observation group(n=31)according to the random number table method.The control group was treated with Lidocaine,and the observation group was treated with Amiodarone.The clinical efficacy,cardiac function indexes(left ventricular ejection fraction[LVEF],left ventricular end-diastolic diameter[LVEDD],left ventricular end-systolic diameter[LVESD])before and after treatment and incidence of adverse reactions of patients were observed between the observation group and the control group.Results The total effective rate of treatment in the observation group was 96.77%,which was higher than 67.74% in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in cardiac function indexes between the two groups before treatment(P>0.05).After treatment,the LVEF,LVEDD,and LVESD of the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05).The LVEF,LVEDD,and LVESD of the observation group after treatment were lower than those of the control group,and the differences were statistically significant(P<0.05).The total incidence rate of adverse reactions in the observation group was 9.68%,which was lower than 35.48%in the control group,and the difference was statistically significant(P<0.05).Conclusion Amiodarone has a good clinical efficacy on severe ventricular arrhythmia,it can effectively improve the cardiac function of patients,and has a higher safety and significant effect,which is worthy of extensive promotion in clinical practice.
龙军成. 胺碘酮与利多卡因治疗重症室性心律失常的效果比较[J]. 中国当代医药, 2020, 27(10): 40-42.
LONG Jun-cheng. Effect comparison of Amiodarone and Lidocaine in the treatment of severe ventricular arrhythmias. 中国当代医药, 2020, 27(10): 40-42.